Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease

被引:0
|
作者
Wang, Yan [1 ,2 ]
Li, Fangyu [1 ,2 ]
Qin, Qi [1 ,2 ]
Li, Tingting [1 ,2 ]
Wang, Qi [1 ,2 ]
Li, Yan [1 ,2 ]
Li, Ying [1 ,2 ]
Jia, Jianping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Innovat Ctr Neurol Disorders, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Neurol, Beijing, Peoples R China
[3] Capital Med Univ, Clin Ctr Neurodegenerat Dis & Memory Impairment, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Collaborat Innovat Ctr Brain Disorders, Beijing, Peoples R China
[5] Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China
来源
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Alzheimer's disease; Apolipoprotein E; Mild cognitive impairment; Biomarker; Cognitive decline; CEREBROSPINAL-FLUID; TAU; METAANALYSIS; LOCI; BETA;
D O I
10.1016/j.tjpad.2025.100065
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Apolipoprotein E epsilon 4 (APOE epsilon 4) bring the higher risk of Alzheimer' Disease (AD). It is essential to evaluate whether the diagnostic performances and critical values of cerebrospinal fluid (CSF) biomarkers are influenced by APOE epsilon 4, which has guiding significance for the clinical practical application. Methods: The differences in CSF biomarkers and their performances between APOE epsilon 4 carriers and non-carriers in distinguishing AD, mild cognitive impairment (MCI) and preclinical AD from normal controls (NCs) were analyzed. The receiver operating characteristic (ROC) curves were generated to compare the area under the curve (AUC) between APOE epsilon 4 carriers and non-carriers, as well as the critical values corresponding Youden Index. Results: In a cross sectional convenience sample of 1610 participants, lower A beta 42 and A beta 42/A beta 40 and higher p-Tau 181/A beta 42 in CSF were observed among APOE epsilon 4 carriers than non-carriers in NC, MCI, and AD groups (P< 0.05). The performance of CSF p-tau/A beta 42 in distinguishing MCI from NC among APOE epsilon 4 carriers was superior to non-carriers [AUC: 0.714 (95%CI: 0.673- 0.752) vs 0.600 (95%CI: 0.564- 0.634), P< 0.001], although it was similar in distinguishing AD from NC between APOE epsilon 4 carriers and non-carriers [AUC: 0.874 (95%CI: 0.835-0.906) vs 0.876 (95%CI: 0.843- 0.904)]. In the longitudinal cohort of 254 participants, the association of CSF A beta 42, A beta 42/A beta 40 and p-Tau181/A beta 42 with cognitive decline were stronger in APOE epsilon 4 carriers compared to non-carriers (P< 0.05). Meanwhile, the critical values were different depending on APOE genotype. Discussion: The CSF level of p-Tau181/A beta 42 was significantly different between APOE epsilon 4 carriers and non-carriers at different stages of AD. The results indicate that the performances of CSF biomarkers are influenced by APOE epsilon 4, which should be considered in the practical application.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice
    Vos, Stephanie J. B.
    Visser, Pieter Jelle
    Verhey, Frans
    Aalten, Pauline
    Knol, Dirk
    Ramakers, Inez
    Scheltens, Philip
    Rikkert, Marcel G. M. Olde
    Verbeek, Marcel M.
    Teunissen, Charlotte E.
    PLOS ONE, 2014, 9 (06):
  • [22] Alzheimer's disease CSF biomarkers: clinical indications and rational use
    Niemantsverdriet, Ellis
    Valckx, Sara
    Bjerke, Maria
    Engelborghs, Sebastiaan
    ACTA NEUROLOGICA BELGICA, 2017, 117 (03) : 591 - 602
  • [23] CSF and Blood Biomarkers for Alzheimer's Disease
    Herskovits, A. Zara
    Ivinson, Adrian J.
    Scherzer, Clemens R.
    Hyman, Bradley T.
    Lindeman, Neal
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (03) : 469 - 469
  • [24] Novel CSF biomarkers for Alzheimer's disease
    Burchell, Jennifer T.
    Panegyres, Peter K.
    FUTURE NEUROLOGY, 2015, 10 (06) : 511 - 514
  • [25] Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease
    Morris, Jill K.
    Uy, Roxanne Adeline Z.
    Vidoni, Eric D.
    Wilkins, Heather M.
    Archer, Ashley E.
    Thyfault, John P.
    Miles, John M.
    Burns, Jeffrey M.
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 58 (04) : 1129 - 1135
  • [26] Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers
    Chetelat, G.
    Fouquet, M.
    REVUE NEUROLOGIQUE, 2013, 169 (10) : 729 - 736
  • [27] No cross-sectional influence of APOE ε4 dose on clinical tests in Alzheimer's disease
    Tractenberg, Rochelle E.
    Aisen, Paul S.
    Hancock, Gregory R.
    Rebeck, G. William
    NEUROBIOLOGY OF AGING, 2009, 30 (08) : 1327 - 1328
  • [28] The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials
    Dumurgier, Julien
    Laplanche, Jean-Louis
    Mouton-Liger, Francois
    Lapalus, Pauline
    Indart, Sandrine
    Prevot, Magali
    Peoc'h, Katell
    Hugon, Jacques
    Paquet, Claire
    JOURNAL OF NEUROLOGY, 2014, 261 (06) : 1187 - 1195
  • [29] The screening of Alzheimer’s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials
    Julien Dumurgier
    Jean-Louis Laplanche
    Francois Mouton-Liger
    Pauline Lapalus
    Sandrine Indart
    Magali Prévot
    Katell Peoc’h
    Jacques Hugon
    Claire Paquet
    Journal of Neurology, 2014, 261 : 1187 - 1195
  • [30] No association of cerebrospinal fluid (CSF) biomarkers with APOE E4, plaque and tangle burden in definite Alzheimer's disease
    Engelborghs, S.
    Sleegers, K.
    Cras, P.
    Brouwers, N.
    Serneels, S.
    De Leenheir, E.
    Martin, J. J.
    Vanmechelen, E.
    Van Broeckhoven, C.
    De Deyn, P. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 22 - 22